U.S. Scrutiny of Chinese Company Could Disrupt U.S. Supply Chain for Key Drugs
15 April 2024 at 15:47
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.